Synapse - Works

Results (116376)

Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

Meeting Abstract

Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Park, J. O.; Cassier, P. A.; Kamath, S. D.; Meng, D. T. W.; Dotan, E.; Kim, R.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC)

Meeting Abstract

Rugo, H. S.; Bardia, A.; Marme, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E. M.; Dalenc, F.; Pardo, P. G.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation

Meeting Abstract

Klempner, S. J.; Weiss, J.; Pelster, M.; Spira, A.; Barve, M.; Ou, S. H. I.; Leal, A.; Bekaii-Saab, T.; Christensen, J. G.; Kheoh, T.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): Update of the LIBRETTO-001 trial

Meeting Abstract

Kroiss, M.; Sherman, E. J.; Wirth, L. J.; Cabanillas, M. E.; Robinson, B.; Subbiah, V.; Drilon, A. E.; Godbert, Y.; Fasnacht, N.; Soldatenkova, V.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial

Meeting Abstract

Necchi, A.; Bajorin, D. F.; Tomita, Y.; Ye, D.; Agerbaek, M.; Enting, D.; Peer, A.; Milowsky, M.; Kobayashi, K.; Grimm, M. O.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study

Meeting Abstract

De Wit, R.; Vaughn, D. J.; Fradet, Y.; Fong, L.; Vogelzang, N. J.; Duran, M. A. C.; Necchi, A.; Petrylak, D. P.; Gerritsen, W. R.; Gurney, H. P.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study

Meeting Abstract

Grivas, P.; Agarwal, P. K.; Al-Ahmadie, H.; Friedlander, T.; Geynisman, D.; Hussain, I.; Lotan, Y.; Morgans, A. K.; Tesic-Schnell, M.; Meeks, J.
Annals of Oncology (2022)

Fulltext@MSK | Save

Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)

Meeting Abstract

Paz-Ares, L.; Johnson, M. L.; Girard, N.; Hann, C. L.; Ahn, M. J.; Nishio, M.; Godard, J.; Laadem, A.; Yoshizuka, N.; Qian, M.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT)

Meeting Abstract

Gounder, M. M.; Jones, R. L.; Chugh, R.; Agulnik, M.; Singh, A.; Van Tine, B. A.; Andelkovic, V.; Choy, E.; Lewin, J.; Ratan, R.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion

Meeting Abstract

Blay, J. Y.; Gelderblom, H.; Rutkowski, P.; Wagner, A.; van de Sande, M.; Gonzalez, A. F.; Stacchiotti, S.; Le Cesne, A.; Alcindor, T.; Serrano, C.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save